Pixelgen Technologies AB is thrilled to announce a successful funding round, raising an impressive 14,700,000 to accelerate its groundbreaking work in precision medicine and cellular biology. This significant investment marks a pivotal moment for the Stockholm-based company, which is on a mission to deliver biology at the highest resolution by unlocking the molecular intricacies of cellular function. Since its founding in 2020 by a team of passionate, experienced innovators and entrepreneurs, Pixelgen has been dedicated to developing cutting-edge tools and technologies that redefine the study of protein interactomics at the single-cell level. At the heart of its innovation is the patented Proximity Network Assay, a technique that offers nanoscale spatial analysis of immune cell proteins with ultra-high capacity. This breakthrough not only underpins the Pixelgen Proxiome Kit but also serves as a foundational technology powering a diverse portfolio of products aimed at translational research.
The new capital will be strategically invested to expand the company鈥檚 research and development efforts, improve scalability, and accelerate the rollout of next-generation diagnostics in immunology, hematology, and cell therapy. By deepening molecular insights and enhancing precision in medicine, Pixelgen is poised to transform clinical practices and therapeutic approaches, addressing unmet needs in healthcare. The expanded funding ensures that the company remains at the forefront of scientific discovery, fostering collaborations with leading academic institutions and industry partners. As Pixelgen continues to revolutionize the way we understand life at a molecular scale, this investment further solidifies its commitment to pushing the boundaries of technology and innovation in the biomedical field.
